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Abstract 
Background: The present study presents the evaluation of the damage in the bone tissue 
resulting from a calvarial defect in rats and the efficiency of exposure to an ozone application 
with an alloplastic bone graft on the calvarial bone damage. 
Materials and methods: Wistar male rats (n = 56) were divided into four groups: a control 
group (n = 14), defect and ozone group (n = 14), defect and graft group (n = 14), and defect, 
graft, and ozone group (n = 14). Under anaesthesia, a circular full-thickness bone defect was 
created in all groups, and the experimental groups were further divided into two sub-groups, 
with seven rats in each group sacrificed at the end of the 4th and 8th weeks. Bone samples were 
dissected, fixed in 10% formalin solution, and decalcified with 5% ethylene-diamine-
tetraacetic acid (EDTA). After the routine follow-up on tissues, immunostaining of 
osteopontin and osteonectin antibodies was applied to sections and observed under a light 
microscope. 
Results: The control group exhibited osteopontin and osteonectin expression in fibroblasts 
and inflammatory cells at the end of the 4th week with an acceleration at the 8th week. Ozone 
administration elucidated new trabecular bone formation by increasing osteoblastic activity. 
Lastly, our observations underscore that a combination of allograft and ozone application 
increased the osteoblast, osteocyte, and bone matrix development at the 4th and 8th weeks. 
Conclusions: Exposure to an ozone application with an alloplastic bone graft on calvarial 
bone damage may induce osteoblastic activity, matrix development, mature bone cell 
formation, and new bone formation in rats. 
Key words: Calvarial defects, osteopontin, osteonectin, rat, immunohistochemistry 
 
 
Introduction 
Calvarial bone defects are associated with trauma, pathology, and non-union of a 
fracture and represent a significant clinical problem (1,2). The osteogenic potential of 
autograft and allografts is known in the field of orthopaedics, plastic surgery, and oral and 
maxillofacial surgery (3,4). Autograft is the current gold standard treatment for bone grafting; 
however, it is limited by the available volume of graft material, donor site morbidity, and 
unpredictable bone resorption (5,6). Allografts are good alternatives to bridge defects, but the 
risk of disease transmission and adverse host immune reactions limits the use of allografts. 
Therefore, improved strategies are urgently needed to better treat craniofacial bone defects 
(7,8). 
Antioxidants applied in defect-induced bone injuries alone do not prevent bone loss. It 
has also been reported that the effect of antioxidants is more prominent, especially after graft 
application. Experimental studies have indicated that osteoprogenitor cell activity is induced 
when the graft application is applied for 4-6 weeks, depending on the type of graft material 
(9). Several types of graft material are available. For instance, allografts are provided from 
donors of different genetic characteristics in the same species (10). There are limitations in the 
convenience of graft types, such as the shortage in the usability of autografts, inappropriate 
characteristics of allografts, and risk of disease transmission in xenografts. For all these 
reasons, researchers have developed an approach of synthetic graft material use in bone 
defects.  
In an experimental study, it has been reported that hyperbaric oxygen and ozone are 
equally effective on bone development in rats induced with calvarial defects (11). In a clinical 
study with topical ozone application, alveolar bone healing is accelerated using postoperative 
long-term systemic ozone application (12). Preparing a superhydrophilic titanium implant 
functionalised with ozone gas can modulate osteoconductivity and inhibit the inflammatory 
response to titanium implants. This superhydrophilic surface has been proposed to be useful 
as an endorsed implantable biomaterial and as a biomaterial for implantation in other tissues 
(13). The effect of ozone treatment in combination with autogenous bone grafts on bone 
healing in rat calvaria has been investigated. Exposure to an ozone application increases new 
bone formation by autogenous bone graft in the rat calvarial defect model (14). 
Clinically, the importance of ossification and fracture healing is well known in rats. It 
has been reported that exposure to ozone application provides good healing in diabetes (15), 
oral mucositis (16), surgical treatment of peri-implantitis (17), bone regeneration (18,19), and 
osteogenesis with calvarial defects in experimental models (20). Many rodent experimental 
animals, including rats, have been used to design bone defect models (21-24). Anatomically, 
these rodent models were studied in the calvarium, femur, mandible, and spine. The defect of 
the calvarium and femur in rats is defined as regions that do not require fixation for 
stabilisation. The calvarial defects are histologically considered an intramembranous model. 
The bone matrix is considered to be less applicable to biomaterials. In other words, it has been 
suggested that the bone matrix is more suitable for endochondral bone model studies. For this 
reason, calvarial defect models should be designed according to appropriate strategies (25). A 
smaller size calvarial defect may recover spontaneously; thus, this was taken into account for 
the purposes of the study. As a result, an 8 mm calvarial defect was created (26). 
Osteonectin protein is involved in the upregulation of mineralisation in osteoblast 
cells, and cell adhesion in osteoclast cells. Osteonectin is a single chain acidic glycoprotein 
that is rich in cysteine, which is synthesised by the cells of an osteoblastic lineage that is 
abundantly expressed in bones undergoing active remodelling. It is connected with type I 
collagen, calcium, and hydroxyapatite and therefore prevents mineralisation (27). Osteopontin 
(also called BSP-1) protein located in the extracellular bone matrix is non-collagenous and 
acts in bone cell functions (28). Osteopontin participates in the upregulation of cell adhesion 
and differentiation in osteoblast cells, and concomitantly in the upregulation of cell adhesion 
and bone resorption in osteoclast cells (29). In a study on two different phases of bone 
belonging to rats, the distribution of N-linked glycoproteins was determined (30). In another 
paper, it was noted that bone sialoprotein binds firmly to collagen type I and hydroxyapatite 
crystals, revealing that sialoprotein and osteopontin are involved in mineralisation (31,32). 
Bone sialoprotein is closely related to the nucleation of amorphous calcium phosphate (33). In 
addition, mice with decreased levels of osteopontin in the bone were reported to be more 
prone to fractures, depending on the varying amount of calcium bound by osteopontin (34). 
Bone, cartilage, dentin, cement, vascular tissue, and epithelial tissue cells express osteopontin 
(35). Osteoclasts, differentiated osteoblasts, and osteocytes release osteopontin and act in 
osteoclast adhesion, resorption, formation, and migration (36). It is known that in remodelling 
bone tissue, cells secrete osteopontin. In addition, osteopontin also contributes to the 
modulation of the inflammatory phase, acting as a pro-inflammatory cytokine (37). 
In this study, we aimed to show the expression of osteonectin and osteopontin proteins 
in rats with calvarial defects by exposure to a topical ozone application with an alloplastic 
graft implant. 
 
Materials and Methods 
a. Ethics and experimental procedure 
Approval of the study was obtained from the Experimental Animal Ethics Committee 
of Dicle University. Experimental animals were obtained from the Health Sciences and 
Application Centre at Dicle University in Diyarbakir, Turkey. All operations on animals were 
performed according to the standards in the Guide for the Care and Use of Laboratory 
Animals (2011, 8th ed.) released by the National Research Council. 
A total of 56 healthy male Wistar rats weighing 280 to 300 g were used for the study. 
The individually housed animals were kept in suitable cages under the conditions of a 12 h 
light and 12 h dark cycle at temperatures of 22˚C ± 2˚C at 50–70% humidity. They were fed a 
standard pellet diet and water ad libitum. At the end of the experiment, no difference was 
observed between experimental and control rats in terms of food / water consumption and 
body weight gain. At the end of the 4th week, 2 rats in the control group, 1 rat in the defect 
and ozone group, and 1 rat in the defect and graft group were seen to have died. At the end of 
the 8th week, 2 rats in the control group, 1 rat in the defect and ozone group, 2 rats in the 
defect and graft group, and 2 rats in the defect, graft and ozone group were found to be dead. 
The tissues of all dead rats were routinely examined histologically.  
 The experimental design for the groups was as follows. For all groups, half of the rats 
were sacrificed at the end of the 4th week, and the remaining half were sacrificed at the end of 
the 8th week. The following are the group designs: 
1. Control group (n = 14) A calvarial bone defect was created without any treatment, 
and the wound was sutured.  
2. Defect and ozone group (n = 14) A calvarial bone defect was created and treated with 
ozone.  
3. Defect and graft group (n = 14) A calvarial bone defect was created, and alloplastic 
bone grafts were applied to the defect.  
4. Defect, graft, and ozone group (n = 14) Calvarial bone defect was created, and 
alloplastic bone grafts plus ozone treatment was applied to the defect.  
b. Calvarial defect model and surgical procedure 
Anaesthesia was performed with 3 mg/kg xylazine (Rompun 2%; Bayer) and 
90 mg/kg Ketamine HCl i.p. (Eczacıbası, Istanbul) (38). After the scalp was shaved and 
disinfected using 70% alcohol, the open frontal bone was uncovered by an incision. The 
periosteum was removed with a periosteal elevator and a trephine bur. Then, the full thickness 
of the calvarial bone defect was created at 8 mm in diameter. An alloplastic graft material 
(Bio-Graft-HT, IFGL Bio Ceramics, India) consisting of a combination of porous biphasic 
60% synthetic hydroxyapatite granules and 40% β-tricalcium phosphate bone graft granules 
with a diameter of 350-500 μm was applied in the defect area of the third and fourth groups. 
In the groups with exposure to ozone, prozone (W&H, Bürmoos, Austria) at a concentration 
of 80% was applied to the prepared graft area from a distance of 1 mm using a Coro tip 
applicator. Prozone was administered for 120 seconds, two times a week with a Coro tip 
applicator. Subcutaneous tissue was sealed with a 6/0 vicryl suture, and the skin was closed 
using a 5/0 silk suture. The skin on the calvarium was completely removed, and the defect 
was taken out with bone forceps (39). 
In this experimental study, a calvarial defect model was created, and 
immunohistochemical observations were evaluated in the four groups. Calvarial defects with 
ozone and graft application were examined both separately and together. Our purpose was to 
investigate the relevance of exposure to the ozone application and healing of the calvarial 
defect at the tissue level immunohistochemically. To show this relationship 
immunohistochemically, osteonectin and osteopontin expressions were evaluated in all 
groups. 
c. Immunohistochemical staining 
Samples of calvarial bone were fixed with 10% formaldehyde solution, decalcified 
with 5% ethylene-diamine-tetraacetic acid (EDTA), dehydrated in a graded series of ethanol, 
and then embedded in paraffin wax. Then, 4–5 µm thick sections were cut with a microtome 
(Leica, Germany) and placed on coated slides. Sections were brought to distilled water and 
washed three times for 5 min in phosphate buffered saline (PBS, pH 7.4) (catalogue number # 
10010023, Thermo Fisher Scientific, US). To unmask antigen sites, slides were incubated 
with EDTA solution in microvawe for 110 minutes at 3x90oC. The sections were washed in 
three times for 5 min in PBS and incubated with hydrogen peroxide (catalogue # TA-015-HP, 
Thermo Fisher Scientific, US) for 20 min. Ultra V block (TA-125-UB, Thermo Fisher 
Scientific, US) was applied to the sections for 8 min prior to the addition of the primary 
antibodies, which were left on overnight osteonectin (SPARC Monoclonal Antibody), 
catalogue # 33-5500, 1:100; and osteopontin monoclonal antibody, catalogue # MA5-17180, 
1:100, both from Thermo Fisher Scientific, US). The sections were washed three times for 5 
min in PBS and then were incubated with biotinylated secondary antibody (catalogue # TP-
125-BN, Thermo Fisher Scientific, US) for 14 min. After washing with PBS, streptavidin 
peroxidase (catalogue # TS-125-HR, Thermo Fisher Scientific, US) was applied to the 
sections for 15 min. The sections were washed three times for 5 min in PBS. 
Diaminobenzidine (catalogue # TA-012-HDC, Thermo Fisher Scientific, US) was applied to 
sections for up to 20 min as a chromogen. Control slides were prepared using the same 
procedure, without primary antibodies. Counterstaining was done using Harris’s haematoxylin 
for 45 s, dehydrated through ascending alcohol and cleared in xylene (Product Number: 
HHS32 Sigma, hematoxylin solution, Harris Modified, Sigma-Aldrich, 3050 Spruce Street, 
Saint Louis, MO, 63103, USA). Slides were mounted with Entellan® (lot: 107961, Sigma-
Aldrich, St. Louis, MO, USA) and examined under a light microscope (Olympus, Germany). 
 
d. Scoring of parameters for immunohistochemistry 
Semi-quantitative scoring (40-42) was determined by examining osteoblastic activity, 
osteocytic activity, osteoclastic activity, and new bone formation in the bone tissue in 15 
different regions within the microscope field, and 10 cells were counted in each area for 
osteonectin and osteopontin expression. These parameters were scored as 0 = no change, 
1 = too weak, 2 = weak, 3 = medium, and 4 = strong. 
 
e. Statistical analysis 
Statistical analyses were performed using the SPSS 22.0 program. The Kruskal Wallis 
variance analysis method was used for non-parametric tests in comparison between groups 
because the data were not distributed according to the Shapiro-Wilk test. According to the 
Kruskal Wallis variance analysis, the difference between the groups was statistically 
significant at p < 0.05. The comparison of the groups with each other was compared with the 
Mann-Whitney U test with Bonferroni correction from multiple comparison tests. In the 
comparison of the pairs between groups, the Bonferroni-corrected Mann-Whitney U test was 
used for multiple comparison tests. 
 
Results 
a. Immunohistochemical results 
For the control group at the 4th week, the osteopontin expression was positive in the 
inflammatory cells of the calvarial bone. The osteopontin positive expression was observed in 
some osteoclast cells (Figure 1a, red arrow), and osteopontin negative expression was 
observed in newly formed small trabecular bone parts (Figure 1a, yellow arrow). However, 
the matrix and osteoblastic activity have not yet increased in the newly formed bone (Figures 
1a and 1a*). For the 8th week of the control group, new bone formation was evidenced by the 
increased activity of the connective tissue cells and osteoblast cells within the defect area. The 
osteoblast cells around the bone trabeculae showed osteopontin positive expression (Figure 
1b, yellow arrow) at the site of the bone matrix (Figures 1b and 1b*). Osteonectin expression 
in the fibroblast and osteoblast cells (Figure 1c, yellow arrow) was found to be positive in the 
control rats for the 4th week. Bone trabeculae increased in the peripheral osteoblastic activity 
(Figures 1c and 1c*). The expansion of bone trabeculae at the 8th week showed positive 
osteonectin expression in the osteoblast cells (Figure 1d, yellow arrow) and matrix structure 
(Figure 1d, red arrow) (Figures 1d and 1d*). In the defect and ozone group, osteopontin 
expression in the fibroblast, osteoclast, and osteoblast cells showed positive expression at the 
4th week and showed osteopontin reaction in new bone trabeculae due to matrix development 
(Figure 2a, yellow arrow) (Figures 2a and 2a*). For the 8th week, osteoblastic activity and 
osteopontin expression in osteocytes (Figure 2b, yellow arrow) showed a positive reaction. 
Bone trabeculae and the matrix for new bone formation became evident (Figures 2b and 2b*). 
An increase in connective tissue cells occurred between the calvarial bone and the defect area 
at the 4th week, whereas the osteonectin expression in the fibroblast and collagen fibres 
(Figure 2c, red arrow) and osteoblast cells (Figure 2c, yellow arrow) was positive (Figures 2c 
and 2c*). For the 8th week, osteonectin expression increased in fibroblast macrophages and 
osteoblast cells. Expansion in new bone trabeculae (Figure 2d, black star) became evident in 
osteocytes (Figure 2d, blue arrow), osteon structures, and osteonectin expression (Figures 2d 
and 2d*). The defect and graft applied group revealed a significant increase in connective 
tissue cells in the graft site by the 4th week. Histologically, we found an increase in 
osteopontin expression of fibroblast cells (Figure 3a, red arrow), inflammatory cells (Figure 
3a, green arrow), and osteoblast cells (Figure 3a, yellow arrow). Small bone trabeculae were 
obviously seen (Figures 3a and 3a*). For the 8th week, osteoblast cells (Figure 3b, yellow 
arrows) close to the calvarial bone area showed the enlargement of new bone trabeculae 
(Figure 3b, black star) with increased osteopontin expression (Figures 3b and 3b*). 
Osteonectin expression in osteoblast cells (Figure 3c, yellow arrows) was positive in the graft 
site for the 4th week of application (Figures 3c and 3c*). For the 8th week, osteonectin 
expression increased in osteoblasts with new bone trabeculae in the graft area. Osteonectin 
reacted positively in osteoblast cells (Figure 3d, yellow arrow), osteocytes (Figure 3d, blue 
arrow), osteoclast cells (Figure 3d, red arrow), and the bone matrix (Figures 3d and 3d*). For 
the defect, graft, and ozone treated group at the end of 4th week, osteopontin expression was 
observed in osteoblast cells (Figure 4a, yellow arrow), and osteocytes were peripherally seen 
in new bone trabeculae (Figure 4a, black star) (Figures 4a and 4a*). For the 8th week, despite 
an increase in cells and collagen fibre structures within the graft site, osteopontin expression 
continued to increase. Mature bone trabeculae became evident. Osteopontin expressions were 
observed in Haversian canals (Figure 4b, red arrow), osteocytes (Figure 4b, yellow arrow), 
and the bone matrix (Figures 4b and 4b*). For the 4th week, osteonectin expression was 
positive in cells between the calvarial bone and the defect area. In the connective tissue cells 
and fibrous structures, osteonectin was positively observed in osteocyte cells (Figure 4c, 
yellow arrow) in trabeculae (Figures 4c and 4c*). For the 8th week, new bone trabeculae 
enlarged, and the osteoblastic activity increased in the area and started to associate with the 
calvarial bone region. Thus, osteonectin expression is increased, and new bone formation is 
accelerated. Osteonectin expression in mature bone cells (Figure 4d, black star) showed a 
positive reaction (Figures 4d and 4d*). In addition, osteoblastic activity, osteocytic activity, 
osteoclastic activity, and new bone formation were statistically determined among all groups 
for osteonectin and osteopontin expressions at the 4th week (Tables 1-2 and 5; Figures 5-6) 
and the 8th week (Tables 3-4 and 6; Figures 7-8). Osteogenesis was eventually promoted in 
the ozone-treated graft application by the 8th week. 
b. Quantification of immunohistochemistry 
The quantification of osteonectin and osteopontin expression in the control, defect and 
ozone, defect and graft, and defect, graft, and ozone groups were performed by evaluating the 
osteoblastic activity, osteocytic activity, osteoclastic activity, and new bone formation at the 
4th and 8th weeks. Results of the present study were given in Tables 1-2 and 5 and Figures 5-6 
for the 4th week and in Tables 3-4 and 6 and Figures 7-8 for the 8th week. 
 
Discussion 
Many clinical studies have been performed on calvarial defect models to evaluate bone 
regeneration related to different diseases (43-46). Histological techniques have been used to 
demonstrate tissue damage (47-49). On the other hand, radiological and mechanical 
techniques have been used for structural and functional evaluations (50-52). Different bone 
graft materials are currently available for regeneration of bone defects in oral and 
maxillofacial surgery, such as the closure of osteotomy openings and alveolar increment (53-
57). Synthetic bone graft materials are available in intra-bone defects, orthognathic surgery, 
facial bone defects, and maxillary sinus ground (54, 58-63). 
Insufficient work has been carried out to show a relationship between exposure to 
ozone application and calvarial defect in rats (11,14,15,64). Kan et al. aimed to compare the 
efficacy of hyperbaric oxygen and systemic ozone, used separately and in combination, on the 
healing of bone defects. They showed that quantitative histological assessment of calvarial 
bone healing showed no total ossification of the critical-size cavity in any of the groups at the 
end of 30 days. However, they also indicated that partial intramembranous and endochondral 
ossification were observed during the calvarial bone defect healing process. Their 
histomorphometric analysis showed more new bone formation in all experimental groups 
compared with the control group on days 5, 15, and 30 (11). Similarly, the effects of systemic 
and topical ozone applications on alveolar bone healing after tooth extraction were 
investigated. In the histomorphometric analysis, they concluded that measurements of 
mineralised and trabecular bone and osteocyte and osteoblast surfaces did not show a 
statistically significant difference between the sacrificed groups at the 14th day. They also 
suggested that there have been no statistically significant findings in the mineralised bone and 
osteoblast field areas between the groups sacrificed on day 28. However, the comparison of 
the histomorphometric parameters of the trabecular bone between days 14 and 28 showed 
higher values on day 28. In addition, they observed statistically significant decreases in 
mineralised bone and osteocyte-osteoblast surfaces for all of the groups sacrificed on day 28 
(12). Accordingly, the effects of exposure to ozone application on calvarial defects and their 
healing time are not well known. However, it is well known that ozone accelerates wound 
healing and increases blood flow. It is dissolved in water or gas for medical purposes. 
Exposure to ozone application can induce several biological responses, such as improving 
blood circulation and accelerated oxygen capacity in ischaemic tissue, upregulating cellular 
antioxidant enzymes, facilitating the activation of the immune system, and supporting the 
secretion of growth factors (65).  
Alpan et al. (15) suggested that treatment with ozone supports the consistency of 
xenograft and promotes regeneration of bone on a model of a calvarial defect in diabetic rats. 
In an experimental study, they asserted that both hyperbaric oxygen and ozone depicted the 
same efficacy to augment bone healing and that the concomitant use of them would be more 
effective (11). Laçin et al. (39) confirmed that ozone has healing effects on bone defects at 4- 
and 8-week intervals, indicating that graft and ozone application is the best practice for new 
bone formation. They emphasised that ozone treatment establishes homeostasis by supporting 
angiogenesis and cell proliferation and induces the synthesis of a group of cytokines, such as 
leukotrienes, interleukins, and prostaglandins. Ozone treatment triggers macrophage 
activation and expedites phagocytosis. It also has a definite effect on bone formation 
compared to the controls in the calvarial defect rate model (64). Ozdemir et al. (14) 
investigated the effect of exposure to ozone application on autogenous bone graft healing in 
calvarial defects. The authors indicated that ozone treatment increased the formation of fresh 
bone with the application of an autogenous bone graft in the calvarial defect rat model. 
Histomorphometrically, they observed that the total bone area in the autogenous bone graft 
with exposure to ozone application group was significantly higher than that of the autogenous 
bone graft group. They also supported that the exposure to the ozone application group 
significantly increased the percentage of total bone area, osteoblast numbers, and new bone 
formation compared to the autogenous bone graft group. In another study, alternative ozone 
therapies on bone regeneration were investigated in the inter-premaxillary suture expansion 
on rats. Ozone treatment expedited the acceleration in the formation of fresh calcified bone in 
the area of suture (66). 
Osteopontin promotes the early differentiation of osteoblasts, their adhesion to the 
bone, and bone formation. Bone cells secrete osteopontin during the process of bone 
remodelling and increase osteopontin expression in response to mechanical stimuli (67,68). 
Choi et al. proposed that patients with ankylosing spondylitis with had significantly higher 
plasma osteopontin, TNF-alpha, and IL-6 levels and more mRNA expression than healthy 
controls (67). Klein-Nulend et al. suggested that osteopontin appeared to stimulate adhesion, 
migration, and bone resorption by osteoclasts. They found that severe loss of osteopontin 
expression in primary bone cells cultured without mechanical stimulation down-regulated 
conditions of use to differentiate the osteoblastic phenotype (68). To understand the interplay 
between systemic and local signalling in bone, they examined the effects of deficiency of the 
bone matrix protein osteopontin on the systemic effects of the parathyroid hormone, 
specifically within osteoblastic cell lineages. Parathyroid hormone receptor (PPR) in 
transgenic mice expressing a constitutively active form of the receptor (caPPR), specifically 
in cells of the osteoblast lineage, have a high bone mass phenotype. In these mice, osteopontin 
deficiency further increased bone mass. They indicated that this increase was associated with 
the conversion of the major intertrabecular cell population from haematopoietic cells to 
stromal/osteoblastic cells and with parallel elevations in the histomorphometric and 
biochemical parameters of bone formation and resorption (69). Ihara et al. aimed to obtain 
insight into the cellular mechanism underlying the phenomena observed in the osteopontin-
deficient bone. They investigated the number of tartrate-resistant acid phosphatase (TRAP)-
positive cells in the bones subjected to parathyroid hormone treatment in cultures. They found 
that the number of TRAP-positive cells increased significantly by PTH in wild type bone; 
however, no such PTH-induced increase in the TRAP-positive cells was observed in 
osteopontin-deficient bones. Their results indicated that the absence of osteopontin suppressed 
the parathyroid hormone-induced increase in bone resorption by preventing the increase in the 
number of osteoclasts in the local milieu of bone (70). Khojasteh et al. compared culture-
expanded bone marrow-derived mesenchymal stem cells and platelet-rich plasma loaded to 
natural bone mineral (bio-oss) and β-tricalcium phosphate for rat calvarial bone repair. 
According to their immunohistochemical observation, they concluded that the positive 
immunoreaction for osteopontin and osteonectin was significant in all groups. Based on these 
positive expressions in the defect area, they concluded that bone formation and mineralisation 
proceeded from the defect border to the centre (71). Double administration of platelet-rich 
plasma has been reported to have no additional benefits for osteonectin and osteocalcin 
expression levels during bone healing in a rabbit cranial defect model. Furthermore, the 
findings revealed that the presence of β-tricalcium phosphate affects osteonectin and 
osteocalcin expressions, suggesting the potential for β-tricalcium phosphate to support early 
bone healing (72). 
In our study, the group with 4 weeks of ozone application revealed a positive reaction 
in osteoclast cells and osteopontin expression in inflammatory cells. Osteoblastic activity 
began to increase within the defect area at the 8th week, and osteopontin expression reacted 
positively in the osteoblasts and bone matrix.  
At the end of the 4th week in the defect and ozone group, fibroblast osteoclasts in the 
defect area and osteopontin expression in the inflammatory cells reacted positively. At week 
8, new bone trabeculae were formed, osteoblastic activity increased, and osteopontin 
expression in osteoblast cells became evident. In the immunohistochemical examination of 
the defect and ozone group, an increase in the connective tissue between the defect area and 
the calvarial bone was observed (Figures 2c and 2c*). Osteonectin was accelerated in 
fibroblasts and osteoblasts. In the 8th week, fibroblast macrophages and positive osteonectin 
expression in osteoblast cells were observed, but new bone trabeculae, osteocytes, and osteon 
structures became evident (Figures 2d and 2d*).  
Positive expression was observed in the osteoblast cells at the graft site at the 4th week 
in the sections of the defect and graft group (Figure 3c), whereas osteoblast cells with new 
bone trabeculae and bone matrix showed an increased expression of osteoblast cells at the 8th 
week (Figures 3d and 3d*).  
In the defect, graft, and ozone group (4th week), osteopontin expression was positive in 
osteoblast osteocytes, whereas new bone was visible in the trabeculae. At the 8th week, mature 
bone trabeculae developed Haversian ducts and increased osteopontin expression in 
osteocytes. In addition, we observed the positive expression of osteonectin in fibroblasts and 
some osteoblasts in the control group (4th week; Figures 1c and 1c*). The defect, graft, and 
ozone application resulted in new bone trabeculae at the 4th week (Figures 4c and 4c*). 
Osteoblast cells showed positive osteonectin expression, and in 8 weeks, the osteon tissues 
and osteocytes reacted positively (Figures 4d and 4d*). Exposure to ozone application is used 
in combination with grafts in rat calvarial defects, and mature bone structure develops after 
about 8 weeks of bone matrix formation and new bone remodelling. 
In the control group, osteonectin expression in the osteoblast cells and bone matrix 
increased in new bone trabeculae at the 8th week (Figures 1d and 1d*).  
Despite the results, there are a few limitations in clinical contribution. Very few 
experimental studies exist on the use of alloplastic graft material with ozone application. Graft 
materials are used to prevent damage to the bones caused by defects in patients, inducing 
osteoblastic activity in bone repair and stimulating osteocyte and trabecular bone 
development. Whereas graft application has a stimulating and curative effect on bone tissue, 
the use of ozone is thought to induce alloplastic graft application by accelerating calvarial 
bone development in rats. 
Statistics analysis: The statistical results of the scoring model of the histological sections of our study 
were evaluated in the Biostatistics Department of Dicle University.  
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Table 1. Evaluation of osteonectin expression results of parameters at 4th week by Kruskal Wallis test 
(*statistically significant result).  
Groups Osteonection expression at 4th week 
Osteoblastic activity Osteocytic activity Osteoclastic activity 
control group Minimum 0 0 2 
Maximum 1 1 4 
Range 1 1 2 
Median 1,00 ,00 3,00 
defect+ozone group Minimum 1 2 2 
Maximum 3 3 3 
Range 2 1 1 
Median 2,00 2,00 2,00 
defect+graft group Minimum 1 2 2 
Maximum 2 3 3 
Range 1 1 1 
Median 2,00 2,00 2,00 
defect+graft+ozone 
group 
Minimum 2 3 0 
Maximum 3 4 2 
Range 1 1 2 
Median 3,00 3,00 1,00 
  Groups N Mean Rank 
Osteonection expression at 4th 
week (Osteoblastic activity) 
control group 7 5,43 
defect+ozone group 7 16,79 
defect+graft group 7 12,71 
defect+graft+ozone group 7 23,07 
Total 28   
Osteonection expression at 4th 
week (Osteocytic activity) 
control group 7 4,00 
defect+ozone group 7 15,57 
defect+graft group 7 15,57 
defect+graft+ozone group 7 22,86 
Total 28   
Osteonection expression at 4th 
week (Osteoclastic activity) 
control group 7 22,50 
defect+ozone group 7 14,71 
defect+graft group 7 16,07 
defect+graft+ozone group 7 4,71 
Total 28   
Osteonection expression at 4th week 
 Osteoblastic activity Osteocytic activity Osteoclastic activity 
Chi-square 18,932 20,803 18,443 
df 3 3 3 
Asymp. Sig. ,000* ,000* ,000* 
 
 
Table 2.  Evaluation of osteopontin expression results of parameters at 4th week by Kruskal Wallis test 
(*statistically significant result). 
  Groups N Mean Rank 
Osteopontin expression at 4th week 
(Osteoblastic activity) 
control group 7 5,43 
defect+ozone group 7 16,79 
defect+graft group 7 12,71 
defect+graft+ozone group 7 23,07 
Total 28   
Osteopontin expression at 4th week 
(Osteocytic activity) 
control group 7 4,00 
defect+ozone group 7 15,57 
defect+graft group 7 15,57 
defect+graft+ozone group 7 22,86 
Total 28   
Osteopontin expression at 4th week 
(Osteoclastic activity) 
control group 7 22,50 
defect+ozone group 7 14,71 
defect+graft group 7 16,07 
defect+graft+ozone group 7 4,71 
Total 28   
Osteopontin expression at 4th week 
(New bone formation) 
control group 7 4,21 
defect+ozone group 7 12,79 
defect+graft group 7 16,86 
defect+graft+ozone group 7 24,14 
Total 28   
Osteopontin expression at 4th week 
 Osteoblastic activity Osteocytic activity Osteoclastic activity New bone formation 
Groups Osteopontin  expression at 4th week 
Osteoblastic activity Osteocytic  
activity 
Osteoclastic 
activity 
New bone 
formation 
control group Minimum 0 0 2 0 
Maximum 1 1 4 1 
Range 1 1 2 1 
Median 1,00 ,00 3,00 ,00 
defect+ozone group Minimum 1 2 2 1 
Maximum 3 3 3 2 
Range 2 1 1 1 
Median 2,00 2,00 2,00 2,00 
defect+graft group Minimum 1 2 2 1 
Maximum 2 3 3 3 
Range 1 1 1 2 
Median 2,00 2,00 2,00 2,00 
defect+graft+ozone 
group 
Minimum 2 3 0 3 
Maximum 3 4 2 4 
Range 1 1 2 1 
Median 3,00 3,00 1,00 3,00 
Chi-
square 
18,932 20,803 18,443 22,612 
df 3 3 3 3 
Asymp. 
Sig. 
,000* ,000* ,000* ,000* 
 
 
 
Table 3.  Evaluation of osteonectin expression results of parameters at 8th week by Kruskal Wallis test 
(*statistically significant result).  
Groups Osteonection expression at 8th week 
Osteoblastic activity Osteocytic activity Osteoclastic activity 
control group Minimum 1 0 0 
Maximum 2 2 2 
Range 1 2 2 
Median 2,00 1,00 1,00 
defect+ozone group Minimum 2 2 0 
Maximum 3 4 1 
Range 1 2 1 
Median 3,00 3,00 1,00 
defect+graft group Minimum 2 2 1 
Maximum 3 4 2 
Range 1 2 1 
Median 2,00 3,00 1,00 
defect+graft+ozone 
group 
Minimum 3 3 0 
Maximum 4 4 1 
Range 1 1 1 
Median 4,00 4,00 ,00 
  Groups N Mean Rank 
Osteonection expression at 8th week 
(Osteoblastic activity) 
control group 7 5,71 
defect+ozone group 7 16,00 
defect+graft group 7 13,00 
defect+graft+ozone group 7 23,29 
Total 28   
Osteonection expression at 8th week 
(Osteocytic activity) 
control group 7 4,43 
defect+ozone group 7 15,86 
defect+graft group 7 14,79 
defect+graft+ozone group 7 22,93 
Total 28   
Osteonection expression at 8th week 
(Osteoclastic activity) 
control group 7 18,00 
defect+ozone group 7 11,86 
defect+graft group 7 19,71 
defect+graft+ozone group 7 8,43 
Total 28   
Osteonection expression at 8th week 
 Osteoblastic activity Osteocytic activity Osteoclastic activity 
Chi-square 18,450 19,208 10,621 
df 3 3 3 
Asymp. Sig. ,000* ,000* ,014* 
 
 
 
 
Table 4.  Evaluation of osteopontin expression results of parameters at 8th week by Kruskal Wallis test 
(*statistically significant result). 
Groups Osteopontin expression at 8th week 
Osteoblastic activity Osteocytic activity Osteoclastic activity New bone formation 
control group Minimum 2 1 1 1 
Maximum 3 3 3 3 
Range 1 2 2 2 
Median 3,00 2,00 2,00 2,00 
defect+ozone group Minimum 2 2 0 3 
Maximum 4 4 1 4 
Range 2 2 1 1 
Median 3,00 3,00 ,00 4,00 
defect+graft group Minimum 1 2 0 3 
Maximum 3 4 2 4 
Range 2 2 2 1 
Median 2,00 3,00 1,00 3,00 
defect+graft+ozone 
group 
Minimum 3 3 0 3 
Maximum 4 4 1 4 
Range 1 1 1 1 
Median 4,00 4,00 ,00 4,00 
  Groups N Mean Rank 
Osteopontin expression at 8th week 
(Osteoblastic activity) 
control group 7 12,29 
defect+ozone group 7 16,50 
defect+graft group 7 7,07 
defect+graft+ozone group 7 22,14 
Total 28   
Osteopontin expression at 8th week 
(Osteocytic activity) 
control group 7 8,50 
defect+ozone group 7 16,00 
defect+graft group 7 11,86 
defect+graft+ozone group 7 21,64 
Total 28   
Osteopontin expression at 8th week 
(Osteoclastic activity) 
control group 7 23,93 
defect+ozone group 7 10,50 
defect+graft group 7 14,57 
defect+graft+ozone group 7 9,00 
Total 28   
Osteopontin expression at 8th week 
(New bone formation) 
control group 7 5,29 
defect+ozone group 7 17,57 
defect+graft group 7 14,29 
defect+graft+ozone group 7 20,86 
Total 28   
Osteopontin expression at 8th week 
 Osteoblastic activity Osteocytic activity Osteoclastic activity New bone formation 
Chi-square 14,479 11,272 15,729 16,237 
df 3 3 3 3 
Asymp. Sig. ,002 ,010 ,001 ,001 
 
 
 
Table 5. Comparison of osteonectin and osteopontin expressions at the 4th week as a binary group with the Bonferroni 
correction Mann whitney U test (1: control group; 2: defect+ozone group; 3: defect+graft group; 4: 
defect+graft+ozone group; p<0,05* is statistically significant result by Bonferroni correction Mann whitney U test).  
Osteonection expression at 4th week 
(Osteoblastic activity) 
P value 
1-2 0,038 <0,05* 
1-3 0,481 >0,05 
1-4 0,000 <0,05* 
2-3 1,000 >0,05 
2-4 0,077 >0,05 
3-4 0,787 >0,05 
Osteonection expression at 4th week 
(Osteocytic activity) 
P value 
1-2 0,034 <0,05* 
1-3 0,034 <0,05* 
1-4 0,000 <0,05* 
2-3 1,000 >0,05 
2-4 0,491 >0,05 
3-4 0,491 >0,05 
Osteonection expression at 4th week 
(Osteoclastic activity) 
P value 
1-2 0,381 >0,05 
1-3 0,752 >0,05 
1-4 0,000 <0,05* 
2-3 1,000 >0,05 
2-4 0,103 >0,05 
3-4 0,007 <0,05* 
Osteopontin expression at 4th week 
(Osteoblastic activity) 
P value 
1-2 0,0038 <0,05* 
1-3 0,481 >0,05 
1-4 0,000 <0,05* 
2-3 1,000 >0,05 
2-4 0,787 >0,05 
3-4 0,077 >0,05 
Osteopontin expression at 4th week 
(Osteocytic activity) 
P value 
1-2 0,034 <0,05* 
1-3 0,034 <0,05* 
1-4 0,000 <0,05* 
2-3 1,000 >0,05 
2-4 0,491 >0,05 
3-4 0,491 >0,05 
Osteopontin expression at 4th week 
(Osteoclastic activity) 
P value 
1-2 0,381 >0,05 
1-3 0,752 >0,05 
1-4 0,000 <0,05* 
2-3 1,000 >0,05 
2-4 0,103 >0,05 
3-4 0,041 <0,05* 
Osteopontin expression at 4th week 
(New bone formation) 
P value 
1-2 0,272 >0,05 
1-3 0,019 <0,05* 
1-4 0,000 <0,05* 
2-3 1,000 >0,05 
2-4 0,048 <0,05* 
3-4 0,533 >0,05 
 
 
Table 6. Comparison of osteonectin and osteopontin expressions at the 8th week as a binary group with the Bonferroni 
correction Mann whitney U test (1: control group; 2: defect+ozone group; 3: defect+graft group; 4: 
defect+graft+ozone group; p<0,05* is statistically significant result by Bonferroni correction Mann whitney U test).  
Osteonection expression at 8th week 
(Osteoblastic activity) 
P value 
1-2 0,079 >0,05 
1-3 0,475 >0,05 
1-4 0,000 <0,05* 
2-3 1,000 >0,05 
2-4 0,475 >0,05 
3-4 0,079 >0,05 
Osteonection expression at 8th week 
(Osteocytic activity) 
P value 
1-2 0,044 <0,05* 
1-3 0,090 >0,05 
1-4 0,000 <0,05* 
2-3 1,000 >0,05 
2-4 0,336 >0,05 
3-4 0,582 >0,05 
Osteonection expression at 8th week 
(Osteoclastic activity) 
P value 
1-2 0,725 >0,05 
1-3 1,000 >0,05 
1-4 0,094 >0,05 
2-3 0,283 >0,05 
2-4 1,000 >0,05 
3-4 0,026 <0,05* 
Osteopontin expression at 8th week 
(Osteoblastic activity) 
P value 
1-2 1,000 >0,05 
1-3 1,000 >0,05 
1-4 0,099 >0,05 
2-3 0,131 >0,05 
2-4 1,000 >0,05 
3-4 0,001 <0,05* 
Osteopontin expression at 8th week 
(Osteocytic activity) 
P value 
1-2 0,417 >0,05 
1-3 1,000 >0,05 
1-4 0,009 <0,05* 
2-3 1,000 >0,05 
2-4 1,000 >0,05 
3-4 0,107 >0,05 
Osteopontin expression at 8th week 
(Osteoclastic activity) 
P value 
1-2 0,007 <0,05* 
1-3 0,144 >0,05 
1-4 0,002 <0,05* 
2-3 1,000 >0,05 
2-4 1,000 >0,05 
3-4 1,000 >0,05 
Osteopontin expression at 8th week 
(New bone formation) 
P value 
1-2 0,015 <0,05* 
1-3 0,163 >0,05 
1-4 0,001 <0,05* 
2-3 1,000 >0,05 
2-4 1,000 >0,05 
3-4 0,641 >0,05 
 
FIGURE LEGENDS 
Figure 1a. Osteopontin immunostaining, control group (4th week). Scale bar = 50 μm. 
Figure 1a*. Negative control group (4th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 1b. Osteopontin immunostaining, control group (8th week). 
Figure 1b*. Negative control group (8th week). Hematoxylene staining. Scale bar = 50 μm.  
Figure 1c. Osteonectin immunostaining, control group (4th week). Scale bar = 50 μm. 
Figure 1c*. Negative control group (4th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 1d. Osteonectin immunostaining, control group (8th week). Scale bar = 50 μm.  
Figure 1d*. Negative control group (8th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 2a. Osteopontin immunostaining, defect+ozone group (4th week). Scale bar = 50 μm.  
Figure 2a*. Negative control group (4th week). Hematoxylene staining. Scale bar = 50 μm.  
Figure 2b. Osteopontin immunostaining, defect+ozone group (8th week). Scale bar = 50 μm.  
Figure 2b*. Negative control group (8th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 2c. Osteonectin immunostaining, defect+ozone group (4th week). Scale bar = 50 μm.  
Figure 2c*. Negative control group (4th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 2d. Osteonectin immunostaining, defect+ozone group (8th week). Scale bar = 50 μm.  
Figure 2d*. Negative control group (8th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 3a. Osteopontin immunostaining, defect+graft group (4th week). Scale bar = 50 μm.  
Figure 3a*. Negative control group (4th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 3b. Osteopontin immunostaining, defect+graft group (8th week). Scale bar = 50 μm.  
Figure 3b*. Negative control group (8th week). Hematoxylene staining. Scale bar = 50 μm.  
Figure 3c. Osteonectin immunostaining, defect+graft group (4th week). Scale bar = 50 μm.  
Figure 3c*. Negative control group (4th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 3d. Osteonectin immunostaining, defect+graft group (8th week). Scale bar = 50 μm.  
Figure 3d*. Negative control group (8th week). Hematoxylene staining. Scale bar = 50 μm.  
Figure 4a. Osteopontin immunostaining, defect+graft+ozone group (4th week). Scale bar = 50 
μm.  
Figure 4a*. Negative control group (4th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 4b. Osteopontin immunostaining, defect+graft+ozone group (8th week). Scale bar = 50 
μm.  
Figure 4b*. Negative control group (8th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 4c. Osteonectin immunostaining, defect+graft+ozone group (4th week). Scale bar 50 
μm.  
Figure 4c*. Negative control group (4th week). Hematoxylene staining. Scale bar = 50 μm. 
Figure 4d. Osteonectin immunostaining, defect+graft+ozone group (8th week). Scale bar = 50 
μm.  
Figure 4d*. Negative control group (8th week). Hematoxylene staining. Scale bar = 50 μm.   
Figure 5. Graphic showing the evaluation of osteonectin expression results for parameters at 
the 4th week in the control and experimental groups. 
Figure 6. Graphic showing the evaluation of osteopontin expression results for parameters at 
the 4th week in the control and experimental groups. 
Figure 7. Graphic showing the evaluation of osteonectin expression results for parameters at 
the 8th week in the control and experimental groups. 
Figure 8. Graphic showing the evaluation of osteopontin expression results for parameters at 
the 8th week in the control and experimental groups. 
 




































